SCHEMBL6166181

SCHEMBL6166181

O=C(c1cc(-c2ccccc2)nc2ccc(Br)cc12)N1CCC[C@@H]1CO

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 5/20 0.55
POLB P06746 1/20 0.50
NPSR1 Q6W5P4 4/20 0.49
MAPT P10636 4/20 0.49
SLC22A12 Q96S37 3/20 0.49
USP2 O75604 2/20 0.49
TSHR P16473 2/20 0.49
KMT2A Q03164 2/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 3/20 0.48
HPGD P15428 1/20 0.48
LMNA P02545 2/20 0.47
ATM Q13315 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
GAA P10253 2/20 0.45
P4HB P07237 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6166486 1.00 RXFP1 (0.55) RXFP1POLBNPSR1MAPTSLC22A12
SCHEMBL6163252 1.00 RXFP1 (0.55) RXFP1POLBNPSR1MAPTSLC22A12
SCHEMBL6165980 0.89 DHODH (0.56) NPSR1SLC22A12TSHRKMT2AMEN1
SCHEMBL6163103 0.89 DHODH (0.56) NPSR1SLC22A12TSHRKMT2AMEN1
SCHEMBL6163110 0.89 DHODH (0.56) NPSR1SLC22A12TSHRKMT2AMEN1
SCHEMBL6166073 0.89 TRPV1 (0.57) POLBTSHRALDH1A1HPGDLMNA
SCHEMBL6161963 0.89 TRPV1 (0.57) POLBTSHRALDH1A1HPGDLMNA
SCHEMBL6163232 0.89 TRPV1 (0.57) POLBTSHRALDH1A1HPGDLMNA
SCHEMBL6163587 0.88 DHODH (0.50) POLBNPSR1MAPTKMT2AALDH1A1
SCHEMBL6164215 0.88 DHODH (0.50) POLBNPSR1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 RXFP1 184/4885POLB 1324/4885NPSR1 38/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 RXFP1 184/4885POLB 1324/4885NPSR1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.